Negus S Stevens, Rice Kenner C
Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
Neuropsychopharmacology. 2009 Mar;34(4):899-911. doi: 10.1038/npp.2008.127. Epub 2008 Aug 13.
Opioid withdrawal can produce a constellation of physiological and behavioral signs, including an increase in opioid self-administration. Different mechanisms mediate different withdrawal signs, and the present study used pharmacologic tools to assess mechanisms underlying withdrawal-associated increases in opioid reinforcement. Five rhesus monkeys were rendered heroin dependent via daily 21-h heroin self-administration sessions. One hour after each heroin self-administration session, monkeys chose between heroin (0-0.1 mg/kg per injection) and food (1 g pellets) during 2-h choice sessions. Under these conditions, heroin maintained a dose-dependent increase in heroin choice, such that monkeys responded primarily for food when low heroin doses were available (0-0.01 mg/kg per injection) and primarily for heroin when higher heroin doses were available (0.032-0.1 mg/kg per injection). Periods of spontaneous withdrawal were intermittently introduced by omitting one 21-h heroin self-administration session, and test drugs were administered during these withdrawal periods. Untreated withdrawal robustly increased heroin choice during choice sessions. Withdrawal-associated increases in heroin choice were completely suppressed by the mu opioid agonist morphine (0.032-0.32 mg/kg/h, i.v.), but not by the alpha-2 noradrenergic agonist clonidine (0.01-0.1 mg/kg/h, i.v.), the dopamine/norepinephrine releaser amphetamine (0.032-0.1 mg/kg/h, i.v.), or the kappa-opioid antagonist 5'-guanidinonaltrindole (1.0 mg/kg, i.m.). The corticotropin-releasing factor 1 antagonist antalarmin (1.0-10 mg/kg per day, i.m.) produced a morphine-like suppression of withdrawal-associated increases in heroin choice in one of three monkeys. These results suggest that mechanisms of withdrawal-associated increases in the relative reinforcing efficacy of opioid agonists may be different from mechanisms of many other somatic, mood-related, and motivational signs of opioid withdrawal.
阿片类药物戒断可产生一系列生理和行为体征,包括阿片类药物自我给药增加。不同机制介导不同的戒断体征,本研究使用药理学工具评估与戒断相关的阿片类药物强化增加的潜在机制。通过每天21小时的海洛因自我给药,使5只恒河猴对海洛因产生依赖。每次海洛因自我给药1小时后,猴子在2小时的选择试验中在海洛因(每次注射0 - 0.1毫克/千克)和食物(1克颗粒)之间进行选择。在这些条件下,海洛因维持了海洛因选择的剂量依赖性增加,使得当有低剂量海洛因(每次注射0 - 0.01毫克/千克)时猴子主要为食物做出反应,而当有高剂量海洛因(每次注射0.032 - 0.1毫克/千克)时主要为海洛因做出反应。通过省略一次21小时的海洛因自我给药来间歇性引入自发戒断期,并在这些戒断期给予受试药物。未经治疗的戒断在选择试验中显著增加了海洛因选择。与戒断相关的海洛因选择增加被μ阿片受体激动剂吗啡(0.032 - 0.32毫克/千克/小时,静脉注射)完全抑制,但未被α2肾上腺素能激动剂可乐定(0.01 - 0.1毫克/千克/小时,静脉注射)、多巴胺/去甲肾上腺素释放剂苯丙胺(0.032 - 0.1毫克/千克/小时,静脉注射)或κ阿片受体拮抗剂5'-胍基纳曲酮(1.0毫克/千克,肌肉注射)抑制。促肾上腺皮质激素释放因子1拮抗剂安他拉美(1.0 - 10毫克/千克/天,肌肉注射)在三只猴子中的一只中产生了类似吗啡的对与戒断相关的海洛因选择增加的抑制作用。这些结果表明,与戒断相关的阿片类激动剂相对强化效力增加的机制可能不同于阿片类药物戒断的许多其他躯体、情绪相关和动机性体征的机制。